# US 2012/0251533 A1 · Monoclonal antibodies against cd30 lacking in fucosyl residues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251533 A1
- Document ID: US20120251533A1
- Status: Published application
- Kind: A1
- Application number: 13/462,566
- Filed: 2012-05-02
- Published: 2012-10-04
- Earliest claimed: 2005-02-18
- Assignees: Medarex, Inc.
- Inventors: Josephine M. CARDARELLI; Amelia Nancy BLACK
- Web page: https://patentgrep.com/patent/US20120251533A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/06: Antianaemics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.

## Claims

### Claim 1

A method of inhibiting growth or activity of CD30+ cells comprising contacting the cells with a defucosylated anti-CD30 antibody under conditions sufficient to induce antibody-dependent cellular cytoxicity (ADCC) of the cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antibody comprises:
(a) a heavy chain variable region comprising SEQ ID NO: 1 and a light chain variable region comprising SEQ ID NO: 4;
(b) a heavy chain variable region comprising SEQ ID NO: 2 and a light chain variable region comprising SEQ ID NO: 5; or
(c) a heavy chain variable region comprising SEQ ID NO: 3 and a light chain variable region comprising SEQ ID NO: 6.

### Claim 3 (depends on 1)

The method of claim 1, wherein the antibody comprises:
(a) a heavy chain variable region CDR1 comprising SEQ ID NO:7, a heavy chain variable region CDR2 comprising SEQ ID NO:10, a heavy chain variable region CDR3 comprising SEQ ID NO:13, a light chain variable region CDR1 comprising SEQ ID NO:16, a light chain variable region CDR2 comprising SEQ ID NO:19; and a light chain variable region CDR3 comprising SEQ ID NO:22;
(b) a heavy chain variable region CDR1 comprising SEQ ID NO:8, a heavy chain variable region CDR2 comprising SEQ ID NO:11, a heavy chain variable region CDR3 comprising SEQ ID NO:14, a light chain variable region CDR1 comprising SEQ ID NO:17, a light chain variable region CDR2 comprising SEQ ID NO:20; and a light chain variable region CDR3 comprising SEQ ID NO:23; or
(c) a heavy chain variable region CDR1 comprising SEQ ID NO:9, a heavy chain variable region CDR2 comprising SEQ ID NO:12, a heavy chain variable region CDR3 comprising SEQ ID NO:15, a light chain variable region CDR1 comprising SEQ ID NO:18, a light chain variable region CDR2 comprising SEQ ID NO:21; and a light chain variable region CDR3 comprising SEQ ID NO:24.

### Claim 4 (depends on 1)

The method of claim 1, wherein the antibody is a monoclonal antibody.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antibody is a human, humanized, or chimeric antibody.

### Claim 6 (depends on 1)

The method of claim 1, wherein the antibody is linked to a toxin.

### Claim 7 (depends on 1)

The method of claim 1, wherein the CD30+ cells mediate an autoimmune disease.

### Claim 8 (depends on 7)

The method of claim 7, wherein the autoimmune disease is selected from the group consisting of autoimmune hemolytic anemia (AIHA), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Systemic Sclerosis, Atopic Dermatitis, Graves' disease, Hashimoto's thyroiditis, Wegner's granulomatosis, Omen's syndrome, chronic renal failure, idiopathic thrombocytopenic purpura (ITP), Crohn's Disease, Ulcerative Colitis, Celiac's Disease, insulin dependent diabetes mellitus (IDDM), acute infectious mononucleosis, HIV, herpes virus associated diseases, multiple sclerosis (MS), hemolytic anemia, thyroiditis, stiff man syndrome, pemphigus vulgaris and myasthenia gravis (MG).

### Claim 9 (depends on 8)

The method of claim 8 wherein the autoimmune disease is ulcerative colitis.

### Claim 10 (depends on 8)

The method of claim 8, wherein the autoimmune disease is Crohn's Disease.
